3% of patients diagnosed with CHC received CHC treatment, a figure which is thought to be lower among people who inject drugs (PWID). 3 In the UK, 90% of individuals infected with hepatitis C virus (HCV) are thought to have acquired the infection through injecting drug use (IDU), and approximately 50% of PWID are estimated to have CHC. 4 Data from Public Health England demonstrate that rapid upscaling of treatment with new therapies is required if further rises in severe CHCrelated disease are to be prevented. 5 The introduction of interferon-free direct-acting antivirals (DAAs) has changed the CHC treatment paradigm. 6, 7 Compared to interferon-based regimens, treatment with DAAs is more efficacious, better tolerated, and of shorter duration. 8 While there was previously no available therapy for CHC with advanced liver disease, recent data show effectiveness of DAA therapy in this population: in an observational cohort study of 467 patients in the UK, of whom 409 had decompensated cirrhosis, DAA therapy led to viral clearance in 81.6% of patients. 9 Sustained virological response was associated with improvements in liver function within 6 months compared with an untreated, matched control group.
Studies suggest that, compared with individuals without HCV infection, patients with CHC have a higher burden of comorbidities (such as psychiatric disorders, co-infection with hepatitis B and/or HIV, atherosclerosis, and chronic kidney disease) in addition to a high prevalence of adverse lifestyle choices such as alcohol and substance abuse. 10, 11 Such factors may pose challenges to effective treatment, particularly for patients who have acquired HCV through IDU. 12, 13 Almost all current DAAs are associated with risks of drug-drug interactions (DDIs), although these differ substantially between agents. 6 Unlike in HIV, where there is a live national dataset for all patients enrolled in treatment (The HIV and AIDS Reporting System; https:// www.gov.uk/guidance/hiv-surveillance-systems), very little is known about the make-up of the UK CHC patient population currently in secondary care-for whom services and treatments will need to be designed and appropriately prioritized in the DAA era. The absence of such information leaves vital clinical, commissioning, and public health questions unanswered. These include how clinical services should be structured to address the specific healthcare needs of the population requiring treatment, the extent of the future resource requirement, the expertise required to provide such care (both in terms of disease management and in laboratory services), and the associated cost implications of this. From a public health perspective, it is unclear whether the population currently enrolled in secondary care services, and therefore those to whom DAAs will be available, reflect the wider UK HCV population and, if not, how efforts to provide more equitable access to care should be focused. Understanding the characteristics and wider health needs of the UK CHC population currently in secondary care, and how this reflects wider population estimates, is essential in this regard.
Furthermore, an appreciation of the factors specifically affecting PWID is vital in widening access to care in this already disadvantaged group.
The aim of this study was to use patient data from the National HCV
Research UK Biobank to describe the demographics of patients currently under specialist hepatology care in the UK who are likely to be eligible for DAA treatment over the next 5 years, and investigate the prevalence of comorbidities, adverse lifestyle factors, and use of medications with potential DDIs involving DAAs. This is with a view to estimating clinical need, informing future service design, and directing public health interventions. The characteristics of patients who acquired HCV through IDU and non-IDU transmission routes were also compared. Univariable logistic regression was performed initially, then odds ratios were adjusted for age to account for differences between acquisition routes. Where indicated, proportions were age-standardized by direct standardization, using the non-IDU group as the reference. Statistical analysis was carried out using Stata 13.1 (StatCorp, Austin, TX).
| PATIENTS AND METHODS

| RESULTS
A total of 6278 patients with CHC from 59 UK specialist centres were included in the analysis. Patient demographics are shown in Table 1 .
Over two-thirds (70.5%) of patients were male, and 85% were white.
Overall, 58% of patients were aged 50 years or above; median age was 52 (interquartile range 43-59) years. Overall, 59.1% of patients had acquired CHC through IDU ( The severity of liver disease at enrolment was recorded by the treating clinician and classified as non-cirrhotic, cirrhosis, or decompensated cirrhosis. The overall prevalence of cirrhosis (compensated and decompensated) was 23.6% across the whole cohort, a figure that was not significantly different between etiological groups.
The prevalence of cirrhosis rose sharply with age, with 36.6% of those over 60 years of age having cirrhosis or decompensated cirrhosis. respectively in patients aged 60 years and above. Depression was the only pathology that became less common with advancing age.
Overall, the most common medications with DDI potential were psychotropic agents (antidepressants, opioids, and hypnotics) (38.6%), antidiabetics (9.3%), immunosuppressants (6.1%), statins (4.9%), and antiretrovirals (4.9%). Table 4 shows the prevalence of In this cohort, 59.1% of patients had acquired HCV through IDU, and 23% were recent injectors. In the UK it is estimated 90% of individuals infected with HCV are thought to have acquired the infection through IDU and approximately 50% of PWID have CHC. 4 As such the number of PWID in this cohort appears disproportionately low, indicating it is likely that PWID are significantly underrepresented in secondary care. This may reflect inequity in access to treatment for these patients under the traditional service model. 3 Although NICE guidelines were changed in 2004 to include current injectors, 14 there is evidence that some hospitals still use this as a criterion for exclusion from treatment. Conversely, age adjusted use of other medication classes by current injectors was significantly lower compared with non-IDU patients (Table 4) , a trend that was mirrored when looking at prevalence of physical comorbidities. Whereas differences observed in psychiatric co-morbidity were largely expected, the opposite trend CI, confidence interval; DDI, drug-drug interaction; IDU, injecting drug user; OR, odds ratio. The non-IDU group was used as the reference group when calculating the unadjusted (unadj.) and age-adjusted (age-adj.) ORs. Given the under-representation of PWID in this secondary care cohort, it is unlikely that reported levels of co-morbidity accurately reflect those of the wider IDU HCV population. Conversely, characteristics of the non-IDU group are likely to be more representative. IDU groups were significantly younger, and therefore less likely to have age related co-morbidities, such as type 2 diabetes and hypercholesterolaemia. Statistical adjustment for age was undertaken, with rates of comorbidity significantly lower following adjustment, but not before.
While we consider this adjusted comparison more appropriate, it assumes a linear effect of increasing age which has the potential to overstate differences. Recorded OLT was significantly more common within the non-IDU group (9.3% non-IDU vs 2.7%-IDU overall).
Metabolic syndrome increases dramatically following OLT, 17 and the substantially higher rates of OLT amongst non-IDU patients may have contributed to the higher rates of statin and anti-diabetic use in this group. It is likely that complications from cirrhosis are commonly replaced by complications of the metabolic syndrome among patients who undergo OLT prior to treatment-a factor which impacts disproportionately on the non-IDU group in this analysis.
In the current study population, 23.6% of patients in this cohort had cirrhosis. Although advanced liver disease in patients with CHC has previously been a barrier to effective CHC treatment, the safety and clinical efficacy of DAAs in patients with decompensated cirrhosis has been widely demonstrated. 9 Patients with advanced liver disease nonetheless represent a vulnerable group who are likely to require more prolonged and complex treatments, will be more susceptible to adverse events, and in whom the potential effects of DDI may be more severe. Rates of cirrhosis increased sharply with age. The proportion of patients commencing treatment with cirrhosis is therefore also likely to increase in line with the projected increases in age of the CHC population under treatment over the next decade. This has service design implications beyond HCV treatment itself, in that expertise in the management of decompensated cirrhosis will need to be integrated within service design -an important point of consideration, particularly in areas where HCV treatment is co-ordinated by infectious disease physicians as opposed to hepatologists, or when considering the allocation of specialist physician time when designing nurse, or community centred services.
The results of our study concur with the high rates of comorbidities and use of medications with DDI potential to DAAs reported among patients with CHC in studies conducted in predominantly specialist settings in the USA 18, 19 and Germany. 20 Our study complements a recent analysis of patients with CHC seen in UK primary care. 21 In this study over two-thirds of patients received medication with a potential DDI to at least one DAA, but less than 1% of patients received medications with contraindications to all four DAAs studied. High levels of comorbidity were also reported, with similar age-related trends as observed in the current study. Both studies concur that patients with CHC in the UK have high levels of non-HCV comorbidity and polypharmacy.
The data used for this analysis were obtained from an opt-in database:
only those data added by clinicians were available, and clinical notes were not accessible, creating a risk of information bias. While the cohort analyzed in this study may not be reflective of the CHC population as a whole, we consider it representative of CHC patients attending UK secondary care, owing to the wide geographic range covered and the types of clinics that participated. Indeed, in the largest centres, 100% of patients were recruited. Lastly our analysis only includes data from patients within secondary care services. A comparison with untreated hepatitis C patients outside of secondary care services may better highlight gaps in current access to treatment. Furthermore, this may better describe the demographics of the IDU population, and provide further insight into how strategies to improve access should be targeted.
Our study demonstrates that the current population of patients with CHC seen in UK secondary care constitutes a complex and heterogeneous group at high risk of disease-drug and drug-drug interactions, both of which can have damaging consequences for the patient and limit effectiveness of therapy. We demonstrate that PWID are currently underrepresented in secondary care clinics, and that this group is disproportionately affected by concomitant burdens of adverse lifestyle factors and mental illness, both of which may further limit effectiveness of treatment.
Upscaling CHC treatment and widening of access to care has the potential to reduce population prevalence and ultimately deaths from CHC-related end-stage liver disease. For this to be achieved, current service models will need be re-evaluated, taking into account the current inequitable access to PWID, and the necessary physician expertise required to manage this complex and comorbid population.
Careful consideration of the clinical and cost implications will be required by providers and payors.
